SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC’s licensing partner receives Complete Response Letter from USFDA

20 May 2026 Evaluate

Sun Pharma Advanced Research Company’s (SPARC) licensing partner -- Ocuvex Therapeutics Inc. has received a Complete Response Letter (CRL) from the United States Food and Drug Administration (USFDA) for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility. The USFDA did not raise any other issues with the PDP-716 NDA.

Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.

Sun Pharma Adv. Res Share Price

242.05 2.65 (1.11%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 440.40
Indegene 517.40
CMS Info Systems 294.40
JITF Infralogistics 299.95
Sagility 39.83
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: